BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts

BACKGROUND: Germline mutations of the BRCA tumour suppressors have been associated with increased risk of pancreatic cancer. Clinical evidence suggests that these patients may be more sensitive to treatment with cisplatin. As the frequency of germline BRCA mutations is low, definitive experimental d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lohse, I, Borgida, A, Cao, P, Cheung, M, Pintilie, M, Bianco, T, Holter, S, Ibrahimov, E, Kumareswaran, R, Bristow, R G, Tsao, M-S, Gallinger, S, Hedley, D W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522629/
https://www.ncbi.nlm.nih.gov/pubmed/26180923
http://dx.doi.org/10.1038/bjc.2015.220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522629/
https://www.ncbi.nlm.nih.gov/pubmed/26180923
http://dx.doi.org/10.1038/bjc.2015.220

Ejemplares similares